Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00111787
Registration number
NCT00111787
Ethics application status
Date submitted
25/05/2005
Date registered
26/05/2005
Date last updated
31/05/2017
Titles & IDs
Public title
Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer
Query!
Scientific title
A Phase II Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of Lapatinib in Combination With Paclitaxel as Neoadjuvant Therapy in Patients With Newly Diagnosed Inflammatory Breast Cancer
Query!
Secondary ID [1]
0
0
EGF102580
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Neoplasms, Breast
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Lapatinib
Treatment: Drugs - Paclitaxel
Experimental: Overall study - A Single arm study with 2 cohorts of participants. Cohort A consists of participants with tumors overexpressing HER2 and/or EGFR. Cohort B consists of participants with tumors expressing EGFR without overexpressing HER2.
Treatment: Drugs: Lapatinib
Daily-monotherapy [1500 milligrams (mg)] for 14 days, then daily combination therapy (with weekly paclitaxel) for 12 weeks
Treatment: Drugs: Paclitaxel
Weekly (80mg/m^2) combination therapy (with daily Lapatinib) for 12 weeks
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of participants with pathologic complete response rate (pCR)
Query!
Assessment method [1]
0
0
pCR was defined as the percentage of participants who achieved an assessment of complete response (CR) following pathologic review of resected tissue. CR was the disappearance of all target lesions. Participants in each cohort with unknown or missing response (i.e., those that did not undergo surgery) were included in the denominator when calculating the percentage. From an efficacy standpoint, the HER2+ population response was considered to be of special interest.
Query!
Timepoint [1]
0
0
Week 12
Query!
Secondary outcome [1]
0
0
Percentage of participants with pCR that underwent surgical resection
Query!
Assessment method [1]
0
0
pCR for participants that underwent surgical (surg) resection was defined as the percentage of participants within each cohort who achieved an assessment of CR following pathologic review of resected tissue. CR was the disappearance of all target lesions. Participants in each cohort that did not undergo surgical resection were excluded from the denominator when calculating the percentage. From an efficacy standpoint, the HER2+ population response was considered to be of special interest.
Query!
Timepoint [1]
0
0
Week 12
Query!
Secondary outcome [2]
0
0
Percentage of participants with objective response rate (ORR) at the end of study (Response evaluation criteria in solid tumor [RECIST])
Query!
Assessment method [2]
0
0
ORR at the end of the study was defined as the number of participants within each cohort who had a confirmed CR or partial response (PR) at the end of the study divided by the total number of participants enrolled in each cohort. CR was the disappearance of all target lesions. PR was at least a 30 percent decrease in the sum of the longest diameter of target lesions, taking as a reference, the Baseline sum longest diameter. Each participant's response was based on the investigator assessment of best response using RECIST criteria. Participants in each cohort with unknown or missing response was treated as non-responders; i.e. they were included in the denominator when calculating the percentage. From an efficacy standpoint, the HER2+ population was considered to be of special interest.
Query!
Timepoint [2]
0
0
Week 14
Query!
Secondary outcome [3]
0
0
Percentage of participants with ORR at the end of study (Clinically Evaluable Skin Disease Criteria)
Query!
Assessment method [3]
0
0
ORR at the end of the study was defined as the number of participants within each cohort who had a confirmed CR or PR at the end of the study divided by the total number of participants enrolled in each cohort. CR was the disappearance of all target lesions. PR was at least a 30 percent decrease in the sum of the longest diameter of target lesions, taking as a reference, the Baseline sum longest diameter. Each participant's response was based on the investigator assessment of best response using Clinically Evaluable Skin Disease Criteria. Participants in each cohort with unknown or missing response was treated as non-responders; i.e. they were included in the denominator when calculating the percentage. From an efficacy standpoint, HER2+ population was considered to be of special interest.
Query!
Timepoint [3]
0
0
Week 14
Query!
Secondary outcome [4]
0
0
Percentage of participants with ORR at the end of study ('Best' of RECIST and Clinically Evaluable Skin Disease Criteria)
Query!
Assessment method [4]
0
0
ORR at the end of the study was defined as the number of participants within each cohort who had a confirmed CR or PR at the end of the study divided by the total number of participants enrolled in each cohort. CR was the disappearance of all target lesions. PR was at least a 30 percent decrease in the sum of the longest diameter of target lesions, taking as a reference, the Baseline sum longest diameter. The best response of the participant was defined by the 'Best' combined response (RECIST and Clinically Evaluable Skin Disease Criteria) provided there is no evidence of disease progression. Participants in each cohort with unknown or missing response was treated as non-responders; i.e. they were included in the denominator when calculating the percentage. From an efficacy standpoint, the HER2+ population was considered to be special interest.
Query!
Timepoint [4]
0
0
Week 14
Query!
Secondary outcome [5]
0
0
Percentage of participants with investigator-Assessed Best Response at the end of monotherapy phase (Day 14) (Clinically Evaluable Skin Disease Criteria)
Query!
Assessment method [5]
0
0
ORR at the end of the monotherapy phase was defined as the percentage of participants within each cohort who had a confirmed CR or PR at the end of lapatinib monotherapy (Day 14) divided by the total number of participants enrolled in each cohort. CR was the disappearance of all target lesions. PR was at least a 30 percent decrease in the sum of the longest diameter of target lesions, taking as a reference, the Baseline sum longest diameter. Each participant's response was based on the investigator assessment of best response using clinically evaluable skin disease criteria. Participants in each cohort with unknown or missing response was treated as non-responders; i.e. they were included in the denominator when calculating the percentage. From an efficacy standpoint, the HER2+ population was considered to be special interest.
Query!
Timepoint [5]
0
0
Day 14
Query!
Secondary outcome [6]
0
0
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Query!
Assessment method [6]
0
0
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE was defined as any untoward medical occurrence that, at any dose that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect, resulted in deterioration in left ventricular cardiac function and caused Grade 3 or 4 interstitial pneumonitis.
Query!
Timepoint [6]
0
0
Up to Week 14, surgical resection and post treatment
Query!
Secondary outcome [7]
0
0
Number of participants with shift from Baseline in hematological toxicity grade
Query!
Assessment method [7]
0
0
Hematology was summarized for hemoglobin (Hb), platelets, white blood cell count (WBC), neutrophils (Neu), lymphocytes by scheduled assessment and also according to the maximum common terminology criteria (CTC) toxicity grade. Baseline was the most recent lab value prior to and within two weeks of the first dose of lapatinib. Change from Baseline was calculated as the value at each visit minus Baseline value.
Query!
Timepoint [7]
0
0
Day 14 and up to Week 23, surg resection and post treatment
Query!
Secondary outcome [8]
0
0
Number of participants with shift from Baseline in clinical chemistry toxicity grade
Query!
Assessment method [8]
0
0
Clinical chemistry was summarized for sodium, potassium (K), bicarbonate (bicarb), albumin (alb), calcium, gamma glutamyl transferase (GGT), creatinine (creat), total bilirubin (TB), alkaline phosphatase (ALP), aspartate amino transferase (AST) and alanine amino transferase (ALT) by scheduled assessment and also according to the maximum CTC toxicity grade. Baseline was the most recent lab value prior to and within two weeks of the first dose of lapatinib. Change from Baseline was calculated as the value at each visit minus Baseline value.
Query!
Timepoint [8]
0
0
Day 14, Week 4, 8, 12, 16, 20, Surg resection and post treatment
Query!
Secondary outcome [9]
0
0
Change from Baseline in vital signs- Systolic blood pressure (SBP) and Diastolic blood pressure (DBP)
Query!
Assessment method [9]
0
0
Vitals signs (SBP and DBP) were assessed from screening until the post treatment phase. Baseline was the most recent blood pressure (BP) mean prior to the first dose of lapatinib. Change from Baseline was calculated as the mean at each visit minus the mean at Baseline.
Query!
Timepoint [9]
0
0
Day 14, Week 1 and up to Week 24, surg resection and post treatment
Query!
Secondary outcome [10]
0
0
Change from Baseline in vital signs- Heart Rate (HR)
Query!
Assessment method [10]
0
0
Vitals signs (HR) were assessed from screening until the post treatment phase. Baseline was the most recent BP mean prior to the first dose of lapatinib. Change from Baseline was calculated as the mean at each visit minus the mean at Baseline.
Query!
Timepoint [10]
0
0
Day 14, Week 1 and up to Week 24, surg resection and post treatment
Query!
Secondary outcome [11]
0
0
Change from Baseline in vital signs- Body temperature
Query!
Assessment method [11]
0
0
Vitals signs (body temperature) were assessed from screening until the post treatment phase. Baseline was the most recent BP mean prior to the first dose of lapatinib. Change from Baseline was calculated as the mean at each visit minus the mean at Baseline.
Query!
Timepoint [11]
0
0
Day 14, Week 1 and up to Week 24, surg resection and post treatment
Query!
Secondary outcome [12]
0
0
Number of participants with abnormal electrocardiogram (ECG) findings
Query!
Assessment method [12]
0
0
ECG was performed at screening and at unscheduled visits. Participants with abnormal clinically significant and abnormal not clinically significant ECG findings was reported.
Query!
Timepoint [12]
0
0
Screening and unscheduled
Query!
Secondary outcome [13]
0
0
Number of participants with change from Baseline in echocardiogram (ECHO) or Multi-gated angiogram (MUGA) results at any post Baseline visit
Query!
Assessment method [13]
0
0
For ECHO and MUGA scans, the left ventricular ejection fraction (percent) was summarized for each scheduled assessment. Absolute change from Baseline was summarized according to the following categories: any increase, 0 to less than 20 percent decrease, >=20 percent decrease or >=20 percent decrease and below the lower limit of normal (LLN). Baseline was the most recent ECOG evaluation prior to the first dose of lapatinib. Change from Baseline was calculated as the value at the post treatment minus Baseline value.
Query!
Timepoint [13]
0
0
Screening, Week 8, 16, 24, post treatment
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
- Tumor accessible for multiple biopsies
- ECOG (Eastern Cooperative Oncology Group) performance status 0-2
- Adequate bone marrow
- Renal and hepatic function
- LVEF (left ventricular ejection fraction) greater than 0% based on ECHO
(echocardiogram) or MUGA (multigated acquisition).
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
- Females who are pregnant or nursing.
- Any unstable, pre-existing major medical condition.
- Received an investigational drug within the past 4 weeks.
- Had major surgery in the past 2 weeks.
- Currently receiving amiodarone or has received amiodarone in the past 6 months.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
11/04/2005
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/11/2006
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
49
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - Campbelltown
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Liverpool
Query!
Recruitment hospital [3]
0
0
GSK Investigational Site - Randwick
Query!
Recruitment hospital [4]
0
0
GSK Investigational Site - South Brisbane
Query!
Recruitment hospital [5]
0
0
GSK Investigational Site - Bedford Park
Query!
Recruitment hospital [6]
0
0
GSK Investigational Site - Box Hill
Query!
Recruitment hospital [7]
0
0
GSK Investigational Site - Ringwood East
Query!
Recruitment postcode(s) [1]
0
0
2560 - Campbelltown
Query!
Recruitment postcode(s) [2]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [3]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [4]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [5]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [6]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [7]
0
0
3128 - Ringwood East
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Florida
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Illinois
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Texas
Query!
Country [4]
0
0
Canada
Query!
State/province [4]
0
0
Ontario
Query!
Country [5]
0
0
France
Query!
State/province [5]
0
0
Bayonne
Query!
Country [6]
0
0
France
Query!
State/province [6]
0
0
Lille Cedex
Query!
Country [7]
0
0
France
Query!
State/province [7]
0
0
Paris cedex 13
Query!
Country [8]
0
0
Israel
Query!
State/province [8]
0
0
Ramat Gan
Query!
Country [9]
0
0
New Zealand
Query!
State/province [9]
0
0
Auckland
Query!
Country [10]
0
0
Spain
Query!
State/province [10]
0
0
Barcelona
Query!
Country [11]
0
0
Spain
Query!
State/province [11]
0
0
Girona
Query!
Country [12]
0
0
Spain
Query!
State/province [12]
0
0
Valencia
Query!
Country [13]
0
0
Tunisia
Query!
State/province [13]
0
0
Sfax
Query!
Country [14]
0
0
Tunisia
Query!
State/province [14]
0
0
Tunis
Query!
Country [15]
0
0
United Kingdom
Query!
State/province [15]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This Study was designed to determine how effective and safe a new investigational drug,
lapatinib, is in combination with paclitaxel in treating patients with newly diagnosed
inflammatory breast cancer. Tumor tissue collected pre-treatment, following 14 days of
treatment and at the time of surgical resection will be examined for pathologic response and
biologic activity by IHC (immunohistochemistry) within the tumor. Treatment will consist of
14 days of lapatinib monotherapy followed by 12 weeks of combination therapy with lapatinib
and paclitaxel. Blood samples for hematology and chemistry panels, MUGA/ECHO exams and
physical exams will be performed throughout the study to monitor safety.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00111787
Query!
Trial related presentations / publications
Boussen H, Cristofanilli M, Zaks T, DeSilvio M, Salazar V, Spector N. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. J Clin Oncol. 2010 Jul 10;28(20):3248-55. doi: 10.1200/JCO.2009.21.8594. Epub 2010 Jun 7.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00111787
Download to PDF